Healthcare

Audeara (ASX:AUA), a hearing-health technology company based in Bowen Hills, Queensland, grew revenue in FY26 while still reporting a going-concern material uncertainty. Its FY26 annual report, signed on 31 August 2026, showed revenue of A$4.45 million, up 17.5 per cent, and a smaller statutory …

Bridge SaaS (ASX:BGE) describes itself as a provider of software-as-a-service and workflow tools for the employment services and National Disability Insurance Scheme (NDIS) sectors, and it also owns NDIS provider businesses in Queensland and New South Wales. The shape of the company is changing. …

Cynata Therapeutics (ASX:CYP), a clinical-stage cell therapy company, saw its position change sharply in mid-2026. Two late-stage trials of its Cymerus platform failed to meet their main efficacy goals, after which the company made its entire workforce redundant and shifted to conserving cash while …

Global Health (ASX:GLH) is a Melbourne-based provider of healthcare software working to move a small, loss-makingBusinesstowards positive cash flow. Its FY2026 results, released on 26 to 27 August 2026, showed a smaller loss on slightly lower revenue, and the company has previously linked its …

Invion (ASX:IVX) is an Australian biotechnology company developing Photosoft, a photodynamic therapy platform in which light-activated compounds are used to treat or image diseased tissue. Its scientific progress and its funding are moving in parallel, but not at the same pace. A skin cancer …

Nexalis Therapeutics (ASX:NX1), formerly InhaleRx Limited, is a Melbourne-based, clinical-stage drug developer working on inhaled therapies for pain and mental health. Its development timetable is now constrained by funding. After a lender cancelled its undrawn facility, the company said in July 2026 that it …

Oakridge International (ASX:OAK), an Adelaide-based developer of nurse-call andAssistive Technologyfor care facilities, reported a small profit and higher revenue for the year to 30 June 2026. The niche healthcare-technology supplier has moved into modest profitability, although the result relied on R&D incentive cash and …